Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ZFHX2 | CTRPv2 | pan-cancer | AAC | 0.17 | 9e-07 |
mRNA | PROX1 | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-07 |
mRNA | VAMP2 | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-07 |
mRNA | CPT1B | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
mRNA | NCOR1 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
mRNA | WDR6 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
mRNA | ZNF71 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
mRNA | KMT2B | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
mRNA | U2AF2 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
mRNA | RP11-106M3.2 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-06 |